Datavault AI Inc. (NASDAQ: DVLT) has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS), a move that would expand an existing technology license and potentially generate royalty revenue for Datavault while allowing it to retain ownership of its underlying intellectual property. The proposed transaction, announced by Datavault AI (NASDAQ: DVLT), matters because it represents a strategic effort to monetize health care data technologies without bearing the full cost of commercialization, which DataMEDS would assume. Datavault AI would also have the right to designate one director to the DataMEDS board following closing, giving it a voice in the venture's direction.
The expanded license would build on DataMEDS' existing PharmacyChain platform and EinsteinRx AI capabilities by incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. This integration is significant because it could accelerate the development of a decentralized health data ecosystem where patients retain control over their information, a growing priority in health care technology. The initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI.
The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions. However, the letter of intent does not obligate either party to complete the transaction, so investors should treat the announcement as a statement of intent rather than a certainty. For Datavault AI, the potential upside lies in royalty revenue from commercialization of the licensed technologies while retaining its intellectual property, a model that could be replicated in other sectors. The company's platform serves multiple industries, including high-performance computing software licensing for sports and entertainment, events and venues, biotech, education, fintech, real estate, healthcare and energy. More details are available in the full press release at https://ibn.fm/Q8IGK.
Datavault AI is headquartered in Philadelphia, PA, and its technology suite offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company's Information Data Exchange enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. Learn more about Datavault AI at https://dvlt.ai. The latest news and updates relating to DVLT are available in the company's newsroom at https://ibn.fm/DVLT.
The announcement was distributed through DefenseWireNews, a specialized communications platform focused on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators and other mission-critical companies. DefenseWireNews is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. For more information on DefenseWireNews' full array of tailored corporate communications solutions, visit the platform's website. Please see full terms of use and disclaimers on the DefenseWireNews website applicable to all content provided by DWN, wherever published or re-published: https://www.DefenseWireNews.com/Disclaimer.
